Mineralys Therapeutics (MLYS) News Today $15.48 +1.01 (+6.98%) Closing price 04:00 PM EasternExtended Trading$15.49 +0.01 (+0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period SR One Capital Management LP Has $49.67 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)August 19 at 8:07 AM | marketbeat.comDeutsche Bank AG Buys 269,283 Shares of Mineralys Therapeutics, Inc. $MLYSAugust 19 at 4:01 AM | marketbeat.comQ3 EPS Estimate for Mineralys Therapeutics Lifted by AnalystAugust 17 at 8:59 AM | marketbeat.comLifesci Capital Issues Positive Forecast for MLYS EarningsAugust 17 at 8:59 AM | marketbeat.comHC Wainwright Has Positive Forecast for MLYS Q3 EarningsAugust 17 at 2:21 AM | americanbankingnews.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider Sells 11,365 Shares of StockAugust 16, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Trading 4.1% Higher - Here's What HappenedAugust 16, 2025 | marketbeat.comVirtu Financial LLC Buys New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)August 16, 2025 | marketbeat.comMineralys Therapeutics Advances Hypertension Drug Toward FDA Filing After Strong Clinical ResultsAugust 16, 2025 | msn.comQ3 EPS Forecast for Mineralys Therapeutics Raised by AnalystAugust 16, 2025 | americanbankingnews.comMineralys Therapeutics (NASDAQ:MLYS) Earns Buy Rating from HC WainwrightAugust 15, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 11,365 SharesAugust 15, 2025 | insidertrades.comMineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Beats Expectations By $0.12 EPSAugust 14, 2025 | marketbeat.comInformed Momentum Co LLC Invests $2.61 Million in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)August 14, 2025 | marketbeat.comMineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comMineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comEarnings Preview For Mineralys TherapeuticsAugust 12, 2025 | benzinga.comMineralys Therapeutics (MLYS) Expected to Announce Earnings on TuesdayAugust 11, 2025 | americanbankingnews.comMineralys Therapeutics (MLYS) Projected to Post Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comMineralys Therapeutics to Announce Q2 Financial Results on August 12August 6, 2025 | msn.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.8% - Here's WhyAugust 5, 2025 | marketbeat.comMineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025August 4, 2025 | globenewswire.comAdam Scott Levy Sells 807 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockJuly 31, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 12,946 SharesJuly 31, 2025 | marketbeat.comAdam Scott Levy Sells 59,925 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockJuly 31, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 8.8% - Time to Buy?July 31, 2025 | marketbeat.comStocks Showing Improved Relative Strength: Mineralys TherapeuticsJuly 31, 2025 | msn.comAdam Scott Levy Sells 807 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockJuly 31, 2025 | insidertrades.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 6.6% - Here's WhyJuly 25, 2025 | marketbeat.comJennison Associates LLC Increases Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)July 20, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $155,453.10 in StockJuly 16, 2025 | insidertrades.comAdam Scott Levy Sells 10,758 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockJuly 15, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 11,366 SharesJuly 15, 2025 | marketbeat.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells 15,884 Shares of StockJuly 15, 2025 | marketbeat.comPromising Investment Opportunity in Mineralys Therapeutics Driven by Lorundrostat’s Clinical SuccessJuly 14, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 6.2% - Time to Sell?July 7, 2025 | marketbeat.comMineralys Therapeutics Announces Positive Phase 3 Launch-HTN Trial Results for Lorundrostat in Uncontrolled Hypertension - NasdaqJuly 2, 2025 | nasdaq.comHere's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn SituationJuly 2, 2025 | finance.yahoo.comMineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of LorundrostatJuly 1, 2025 | msn.comMineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for LorundrostatJune 30, 2025 | globenewswire.comMLYS - Mineralys Therapeutics Inc Key Metrics - MorningstarJune 26, 2025 | morningstar.comMResearch Analysts Issue Forecasts for MLYS Q2 EarningsJune 19, 2025 | marketbeat.comPromising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment AppealJune 18, 2025 | tipranks.comMineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock JumpsJune 17, 2025 | benzinga.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 5.6% - Should You Buy?June 17, 2025 | marketbeat.comMineralys Therapeutics' (MLYS) Buy Rating Reaffirmed at HC WainwrightJune 17, 2025 | marketbeat.comPositive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy RatingJune 17, 2025 | tipranks.comMineralys Therapeutics stock jumps after positive kidney disease trial dataJune 17, 2025 | investing.comMineralys Therapeutics Shares Climb on Strong Results from Kidney Disease TrialJune 17, 2025 | msn.comMineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and AlbuminuriaJune 17, 2025 | globenewswire.com Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Media Mentions By Week MLYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼0.980.47▲Average Medical News Sentiment MLYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼215▲MLYS Articles Average Week Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LNTH News Today APLS News Today MLTX News Today PTGX News Today MIRM News Today MTSR News Today BHC News Today KYMR News Today SRRK News Today AMRX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access